Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab for Prevention of Liver Failure in Pediatric Indeterminate Severe Hepatitis (SHIELD)
NCT07744919Phase 2Not yet recruiting
- Sponsor
- Children's Healthcare of Atlanta
- Start
- Sep 2026
- Primary completion
- Sep 2031
- Countries
- 1
01
Overview
A Phase 2 trial of emapalumab in hepatitis, sponsored by Children's Healthcare of Atlanta. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
emapalumab
03
Conditions
hepatitis
Beyond the preview
Go deeper on NCT07744919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07744919.